The $1.7 million grant from Open Philanthropy is a positive development for Evotec SE, as it provides funding for the discovery and development of RNA-targeting therapeutics against Henipaviruses. This could potentially lead to first-in-class treatments, which would be beneficial for the company's growth and reputation in the biotech industry. As a result, the stock price is likely to go up in the short term.